|
|
| APPY (NASDAQ) - ASPENBIO PHARM | |
pop up description layer
Active Signal: None| Most Recent | Close | Change | | 2010-09-03 | $0.55 | $0.03 (-5.17%)  |
|
You need to upgrade your Flash Player
Internet Stock Research Resources
| |  Public Information | | Latest News |
 Stock Charts | |
| | | Company News | | | - AspenBio Pharma to Present at the Canaccord Genuity 30th Annual Growth Conference
CASTLE ROCK, CO -- (Marketwire) -- 08/06/10 -- AspenBio Pharma,
Inc. (NASDAQ: APPY), has been invited to present at the Canaccord
Genuity 30th Annual Growth Conference. The conference will be held at
the InterContinental Boston on August 10-12, 2010.
Company management is scheduled to present on Thursday, August 12,
2010 at 10:00 a.m. Eastern Time with one-on-one meetings held
throughout the day. Management will discuss the company's recent
activities surrounding its AppyScore(TM) Test, the first blood-based
test designed as an aid in the diagnosis of human appendicitis.
- AspenBio Pharma Reports AppyScore(TM) ELISA-Based Pivotal Trial Results and Outlines Plans for AppyScore Cassette-Based Test
Conference Call Scheduled for 8:00 A.M., E.T. July 20, 2010
CASTLE ROCK, CO -- (Marketwire) -- 07/19/10 -- AspenBio Pharma,
Inc. (NASDAQ: APPY) reported results today from the Company's
recently completed AppyScore(TM) ELISA-based pivotal clinical trial.
The study was designed to evaluate the utility of the AppyScore
blood-based test in aiding in the evaluation of patients suspected of
having acute appendicitis.
- AspenBio Pharma Updates on AppyScore(TM) FDA 510(k) Filing and Data Analysis
CASTLE ROCK, CO -- (Marketwire) -- 06/07/10 -- AspenBio Pharma,
Inc. (NASDAQ: APPY) reported today that the Company is performing
additional data analysis on its recently completed pivotal clinical
trial. As a result, the submission of its 510(k) application for
AppyScore with the Food and Drug Administration ("FDA") will not
occur as previously anticipated by late June 2010. The Company has
determined that additional data analysis is necessary, as there was
unexplained variability in results from site to site in the initial
draft of the statistical analysis report. The continued analysis of
these data and related work is AspenBio's highest priority and, upon
completion, the Company will provide additional information.
"There is significant variability among clinical sites that we must
reconcile to fully understand the results," said Steve Lundy,
AspenBio Pharma's President and Chief Executive Officer. "Our
commitment is to conduct a rigorous data analysis and we will report
on this analysis as soon as we are able."
- AspenBio Pharma Announces Registered Direct Common Stock and Warrant Offering of $10.0 Million
CASTLE ROCK, CO -- (Marketwire) -- 04/30/10 -- AspenBio Pharma,
Inc. (NASDAQ: APPY) announced today that it has entered into
definitive agreements with certain new and existing institutional
investors to sell an aggregate of 2,409,639 units, with each unit
consisting of (i) one share of its common stock, no par value per
share ("Common Stock") and (ii) one warrant to purchase 0.285 shares
of Common Stock, in a registered direct offering for gross proceeds
of approximately $10.0 million, before deducting placement agent's
fees and estimated offering expenses. The investors have agreed to
purchase the units for a negotiated price of $4.15 per unit. The per
share exercise price of the warrants is $4.82. The warrants are
exercisable beginning on the date of closing of this offering and
will expire on the date that is eight months from the date of
closing.
The securities described above are being offered directly by AspenBio
Pharma pursuant to an effective shelf registration statement
previously filed with the Securities and Exchange Commission. The
company anticipates that the net proceeds from the offering will be
used for product development, 501(k) submission related activities,
working capital and general corporate purposes. The closing of this
offering is expected to occur on or about May 5, 2010, subject to the
satisfaction of customary closing conditions.
- AspenBio Continues to Strengthen Leadership Adding Steve Lundy as CEO
Daryl Faulkner Remains in Leadership Role as Executive Chairman
CASTLE ROCK, CO -- (Marketwire) -- 03/25/10 -- AspenBio Pharma, Inc.
(NASDAQ: APPY) reported that Steve Lundy has joined the company as
Chief Executive Officer and will become a member of the Board of
Directors. The addition of Mr. Lundy is part of succession and
organizational planning that was initiated in the latter half of
2009. Daryl Faulkner, who served as Interim CEO in 2009 will
relinquish that role but will continue as Executive Chairman of the
company and will focus more on strategic matters.
- AspenBio Completes Patient Enrollment of AppyScore Clinical Trial to Support FDA 510(k) Submission
CASTLE ROCK, CO -- (Marketwire) -- 03/23/10 -- AspenBio Pharma,
Inc. (NASDAQ: APPY) has completed patient enrollment for its
AppyScore(TM) pivotal clinical trial designed to evaluate 800
patients suspected of having acute appendicitis. The study has now
advanced to the data analysis phase.
The company estimates approximately six to eight weeks will be
required to independently review and validate final clinical and
assay data and statistical analysis. Upon completion of this analysis
the data will then be included in the FDA 510(k) package. The company
continues to plan on completing the FDA 510(k) submission in the
second quarter of 2010.
- More APPY News..
| |
|
|
|
|
InvestSignal.com: Discovering Stock Market Opportunities Every Day.
HOME ||
Terms of Use || Privacy Policy || FAQ
|| Contact Us
Copyright © 2009-2010 InvestSignal.com. All rights reserved.
Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI).
TERMS OF USE: The materials provided on this site is for informational purposes only, and no mention of a particular security constitutes a recommendation to buy, sell,
or hold that or any other security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
InvestSignal.com and its publishers cannot and do not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability
or profitability of any particular investment, or the potential value of any investment or informational source. You, the reader, are solely responsible for
your own investment research and decisions, and should seek the advice of qualified licensed investment and tax professionals before making any investment.
This site represents opinions of the authors and is not in any way affiliated with any companies listed. InvestSignal.com, its publishers or the authors
shall not be liable for any factual errors in the content or for any actions taken in reliance thereon. InvestSignal.com, its publishers and the authors may
hold positions in any of the securities listed. Use of this website equals to your agreement with these terms without any conditions.
|
